0JJM
vs
O
OMX Copenhagen 25
0JJM
Over the past 12 months, 0JJM has underperformed OMX Copenhagen 25, delivering a return of 0% compared to the OMX Copenhagen 25's +9% growth.
Stocks Performance
0JJM vs OMX Copenhagen 25
Performance Gap
0JJM vs OMX Copenhagen 25
Performance By Year
0JJM vs OMX Copenhagen 25
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
